文献速递妇科生殖医学

多巴胺激动剂靶向血管生成治疗子宫内膜异位症

Use of dopamine agonists to target angiogenesis in women with endometriosis.
PubMed 文献 · Hum Reprod · 2021-01-01

本文综述了实验与临床数据,探讨多巴胺激动剂(DAs)通过靶向血管生成治疗子宫内膜异位症的潜力。实验模型中DAs下调促血管生成通路、上调抗血管生成通路,减少病灶大小;人类研究中DAs可减轻疼痛和子宫内膜瘤体积,且不影响排卵。数据支持DAs用于子宫内膜异位症的药物治疗,联合己酮可可碱可能是一种新策略。

要点

  • DAs通过抑制VEGF分泌及受体2失活阻断病灶血管生成。
  • 人类研究显示DAs可减轻疼痛和缩小子宫内膜瘤,同时维持排卵。
  • DAs联合己酮可可碱可能从不同角度靶向疾病,优于现有治疗。

核心结论

  • 数据支持多巴胺激动剂用于子宫内膜异位症的药物治疗,可缩小病灶和减轻疼痛并维持排卵。

研究设计与样本

  • 综述实验与临床数据,评估多巴胺激动剂靶向血管生成治疗子宫内膜异位症的概念。

主要发现

  • 实验模型中溴隐亭、卡麦角林、喹高利特下调促血管生成通路并上调抗血管生成通路,阻断细胞增殖并缩小病灶。
  • VEGF分泌受损及其2型受体失活是关键事件,VEGF抑制还降低病灶神经纤维密度。
  • 人类中喹高利特对病灶有类似效果,DAs减轻疼痛和子宫内膜瘤大小。
  • DAs治疗后Serpin-1(编码PAI-1的基因)下调20倍。
  • 己酮可可碱(一种PAI-1)提高子宫内膜异位症女性的妊娠率。

临床怎么用

  • 对于希望受孕的子宫内膜异位症患者,可考虑使用DAs在维持排卵的同时缩小病灶和减轻疼痛。
  • DAs联合己酮可可碱可能作为与现有药物不同角度的联合治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endometriosis requires medical management during a woman's reproductive years. Most treatments aim to create a hypoestrogenic milieu, but for patients wishing to conceive, drugs that allow normal ovarian function are needed. Targeting angiogenesis, a hallmark of the disease, using dopamine agonists (DAs) is a promising strategy for endometriosis treatment. Herein, we review experimental and clinical data that investigate this concept. In experimental models of endometriosis, DAs (bromocriptine, cabergoline, quinagolide) downregulate proangiogenic and upregulate antiangiogenic pathways in inflammatory, endothelial and endometrial cells, blocking cellular proliferation and reducing lesion size. Impaired secretion of vascular endothelial growth factor (VEGF) and inactivation of its receptor type-2 are key events. VEGF inhibition also reduces nerve fiber density in lesions. In humans, quinagolide shows similar effects on lesions, and DAs reduce pain and endometrioma size. Moreover, a 20-fold downregulation of Serpin-1, the gene that encodes for plasminogen activator inhibitor 1 (PAI-1), has been observed after DAs treatment. Pentoxifylline, a PAI-1, increases pregnancy rates in women with endometriosis. Thus, the data support the use of DAs in the medical management of endometriosis to reduce lesion size and pain while maintaining ovulation. A combined approach of DAs and pentoxifylline is perhaps a smart way of targeting the disease from a completely different angle than current medical treatments.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Pellicer N, Galliano D, Herraiz S, et al. Use of dopamine agonists to target angiogenesis in women with endometriosis. Hum Reprod. 2021. PMID: 33355352. doi:10.1093/humrep/deaa337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。